While the expression of GR is decreased during breast cancer development (Perou et al, 2000; Sørlie et al, 2001; Lien et al, 2006; Conde et al, 2008; Buxant et al, 2010), studies have shown that GR activation by GCs can inhibit cell proliferation in estrogen receptor (ER)‐positive breast cancer (Tonsing‐Carter et al, 2019). Here, ESR1 is linked to breast carcinoma.